Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss

Arbutus Biopharma Corp

Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).
28% of subjects on imdusiran + 24 weeks of IFN achieved HBsAg below lower limit of quantification with anti-HBs.
Imdusiran followed by VTP-300 maintained lower HBsAg levels; more subjects qualified to stop NA therapy and remain off therapy.
Additional on-treatment, follow-up, and NA discontinuation data to be presented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.